Home › Companies › OCULAR THERAPEUTIX INC. › 2023-2024
Compiled from SEC Form N-PX filings and OCULAR THERAPEUTIX INC.’s Form 8-K, filed June 14, 2024 (Item 5.07 on EDGAR). Page generated October 18, 2026.
Meeting of June 12, 2024: 6 items on OCULAR THERAPEUTIX INC.’s Form 8-K, filed June 14, 2024: 2 elected · 4 approved.
None.
Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided
Explore OCULAR THERAPEUTIX INC. in the interactive database Compare manager voting policies
These tallies are OCULAR THERAPEUTIX INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 14, 2024 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: Adrienne L. Graves, Ph.D. | 85,368,917 | -- | -- | 389,155 | 35,036,868 | 99.5% | Elected | — |
| Elect Director: Charles Warden | 78,505,842 | -- | -- | 7,252,230 | 35,036,868 | 92% | Elected | — |
| (2) The Company's stockholders approved a non-binding, advisory proposal regarding the compensation of the Company's named executive officers. | 76,321,509 | 9,265,164 | 171,399 | -- | 35,036,868 | 89% | Approved | — |
| (3) The Company's stockholders approved Amendment No. 3 to increase the number of shares of common stock of the Company issuable under the 2021 Stock Incentive Plan by 7,000,000 shares. | 84,021,277 | 1,650,947 | 85,848 | -- | 35,036,868 | 98% | Approved | — |
| (4) The Company's stockholders approved the proposal to amend the Company's Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of common stock from 200,000,000 to 400,000,000. | 112,604,813 | 8,024,680 | 165,447 | -- | -- | 93% | Approved | — |
| (5) The Company's stockholders ratified the selection of PricewaterhouseCoopers LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2024. | 119,634,478 | 859,430 | 301,032 | -- | -- | 99.2% | Approved | — |
Source: OCULAR THERAPEUTIX INC., Form 8-K, filed with the SEC on June 14, 2024 — read the filing on EDGAR.
Each item below shows how the 138 asset managers that disclosed a OCULAR THERAPEUTIX INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.
Combines 4 wordings of this item as funds reported it.
99.5% Majority: yes · of votes cast
Description as filed by funds: To elect two Class I directors, each to serve until the 2027 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified: Adrienne L. Graves, Ph.D.
OCULAR THERAPEUTIX INC.’s own tally for this item (“Elect Director: Adrienne L. Graves, Ph.D.”): 85,368,917 for, 389,155 withheld, per its Form 8-K filed June 14, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “(1) The Company's stockholders elected Adrienne L. Graves, Ph.D. and Charles Warden as Class I directors to serve until the 2027 Annual Meeting of Stockholders, each such director to hold office until her or his successor has been duly elected and qualified.”
Support: 99.5% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 39 asset managers below reported 14,390,145 for.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 7,022,809 | 0 | 0 | 0 | For |
| Fidelity | 2,186,730 | 0 | 0 | 0 | For |
| TIAA | 824,620 | 0 | 0 | 0 | For |
| T. Rowe Price | 774,875 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 750,100 | 0 | 0 | 0 | For |
| Invesco | 519,167 | 0 | 0 | 0 | For |
| BlackRock | 505,753 | 0 | 0 | 0 | For |
| Charles Schwab | 316,471 | 0 | 0 | 0 | For |
| Equitable | 311,496 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 176,912 | 0 | 0 | 0 | For |
| State Street | 157,212 | 0 | 0 | 0 | For |
| PARADIGM FUNDS | 140,000 | 0 | 0 | 0 | For |
| Lincoln Financial | 92,900 | 0 | 0 | 0 | For |
| 1290 Funds | 80,111 | 0 | 0 | 0 | For |
| John Hancock | 66,703 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 56,981 | 0 | 0 | 0 | For |
| Goldman Sachs | 48,693 | 0 | 0 | 0 | For |
| Pacific Life | 38,685 | 0 | 0 | 0 | For |
| Voya | 36,956 | 0 | 0 | 0 | For |
| Global X | 36,197 | 0 | 0 | 0 | For |
| Brighthouse | 34,296 | 0 | 0 | 0 | For |
| ProShares | 34,027 | 0 | 0 | 0 | For |
| Nationwide | 31,395 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 21,619 | 0 | 0 | 0 | For |
| SEI | 18,400 | 0 | 0 | 0 | For |
Showing the 25 largest of 39 asset managers. See all 39 in the interactive database.
Combines 3 wordings of this item as funds reported it.
92% Majority: yes · of votes cast
Description as filed by funds: To elect two Class I directors, each to serve until the 2027 Annual Meeting of Stockholders and until his or her successor is duly elected and qualified: Charles Warden
OCULAR THERAPEUTIX INC.’s own tally for this item (“Elect Director: Charles Warden”): 78,505,842 for, 7,252,230 withheld, per its Form 8-K filed June 14, 2024 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “(1) The Company's stockholders elected Adrienne L. Graves, Ph.D. and Charles Warden as Class I directors to serve until the 2027 Annual Meeting of Stockholders, each such director to hold office until her or his successor has been duly elected and qualified.”
Support: 92% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 39 asset managers below reported 13,479,517 for, 910,628 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 7,022,809 | 0 | 0 | 0 | For |
| Fidelity | 2,186,730 | 0 | 0 | 0 | For |
| TIAA | 824,620 | 0 | 0 | 0 | For |
| T. Rowe Price | 774,875 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 0 | 0 | 0 | 750,100 | Withhold |
| Invesco | 519,167 | 0 | 0 | 0 | For |
| BlackRock | 505,753 | 0 | 0 | 0 | For |
| Charles Schwab | 316,471 | 0 | 0 | 0 | For |
| Equitable | 206,546 | 0 | 0 | 104,950 | Mixed |
| QUANTITATIVE MASTER SERIES LLC | 176,912 | 0 | 0 | 0 | For |
| State Street | 157,190 | 0 | 0 | 22 | For |
| PARADIGM FUNDS | 140,000 | 0 | 0 | 0 | For |
| Lincoln Financial | 92,900 | 0 | 0 | 0 | For |
| 1290 Funds | 80,111 | 0 | 0 | 0 | For |
| John Hancock | 66,703 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 56,981 | 0 | 0 | 0 | For |
| Goldman Sachs | 48,693 | 0 | 0 | 0 | For |
| Pacific Life | 38,685 | 0 | 0 | 0 | For |
| Voya | 36,956 | 0 | 0 | 0 | For |
| Global X | 0 | 0 | 0 | 36,197 | Withhold |
| Brighthouse | 34,296 | 0 | 0 | 0 | For |
| ProShares | 34,027 | 0 | 0 | 0 | For |
| Nationwide | 30,436 | 0 | 0 | 959 | For |
| Bridge Builder Trust | 21,619 | 0 | 0 | 0 | For |
| SEI | 0 | 0 | 0 | 18,400 | Withhold |
Showing the 25 largest of 39 asset managers. See all 39 in the interactive database.
Combines 3 wordings of this item as funds reported it.
93% Approved · of votes cast
Description as filed by funds: To approve an amendment to our Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of our common stock from 200,000,000 shares to 400,000,000 shares.
OCULAR THERAPEUTIX INC.’s own tally for this item (“(4) The Company's stockholders approved the proposal to amend the Company's Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of common stock from 200,000,000 to 400,000,000.”): 112,604,813 for, 8,024,680 against — passed, per its Form 8-K filed June 14, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “(4) The Company's stockholders approved the proposal to amend the Company's Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of common stock from 200,000,000 to 400,000,000.”
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 39 asset managers below reported 14,390,132 for, 13 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 7,022,809 | 0 | 0 | 0 | For |
| Fidelity | 2,186,730 | 0 | 0 | 0 | For |
| TIAA | 824,620 | 0 | 0 | 0 | For |
| T. Rowe Price | 774,875 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 750,100 | 0 | 0 | 0 | For |
| Invesco | 519,167 | 0 | 0 | 0 | For |
| BlackRock | 505,753 | 0 | 0 | 0 | For |
| Charles Schwab | 316,471 | 0 | 0 | 0 | For |
| Equitable | 311,496 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 176,912 | 0 | 0 | 0 | For |
| State Street | 157,199 | 13 | 0 | 0 | For |
| PARADIGM FUNDS | 140,000 | 0 | 0 | 0 | For |
| Lincoln Financial | 92,900 | 0 | 0 | 0 | For |
| 1290 Funds | 80,111 | 0 | 0 | 0 | For |
| John Hancock | 66,703 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 56,981 | 0 | 0 | 0 | For |
| Goldman Sachs | 48,693 | 0 | 0 | 0 | For |
| Pacific Life | 38,685 | 0 | 0 | 0 | For |
| Voya | 36,956 | 0 | 0 | 0 | For |
| Global X | 36,197 | 0 | 0 | 0 | For |
| Brighthouse | 34,296 | 0 | 0 | 0 | For |
| ProShares | 34,027 | 0 | 0 | 0 | For |
| Nationwide | 31,395 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 21,619 | 0 | 0 | 0 | For |
| SEI | 18,400 | 0 | 0 | 0 | For |
Showing the 25 largest of 39 asset managers. See all 39 in the interactive database.
Combines 3 wordings of this item as funds reported it.
98% Approved · of votes cast
Description as filed by funds: To approve an amendment to the Ocular Therapeutix, Inc. 2021 Stock Incentive Plan, as amended, to increase the number of shares of common stock issuable thereunder by 7,000,000 shares.
OCULAR THERAPEUTIX INC.’s own tally for this item (“(3) The Company's stockholders approved Amendment No. 3 to increase the number of shares of common stock of the Company issuable under the 2021 Stock Incentive Plan by 7,000,000 shares.”): 84,021,277 for, 1,650,947 against — passed, per its Form 8-K filed June 14, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “(3) The Company's stockholders approved Amendment No. 3 to increase the number of shares of common stock of the Company issuable under the 2021 Stock Incentive Plan by 7,000,000 shares.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 39 asset managers below reported 14,378,592 for, 11,553 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 7,022,809 | 0 | 0 | 0 | For |
| Fidelity | 2,186,730 | 0 | 0 | 0 | For |
| TIAA | 824,620 | 0 | 0 | 0 | For |
| T. Rowe Price | 774,875 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 750,100 | 0 | 0 | 0 | For |
| Invesco | 519,167 | 0 | 0 | 0 | For |
| BlackRock | 505,753 | 0 | 0 | 0 | For |
| Charles Schwab | 316,471 | 0 | 0 | 0 | For |
| Equitable | 311,496 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 176,912 | 0 | 0 | 0 | For |
| State Street | 157,190 | 22 | 0 | 0 | For |
| PARADIGM FUNDS | 140,000 | 0 | 0 | 0 | For |
| Lincoln Financial | 92,900 | 0 | 0 | 0 | For |
| 1290 Funds | 80,111 | 0 | 0 | 0 | For |
| John Hancock | 66,703 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 56,981 | 0 | 0 | 0 | For |
| Goldman Sachs | 48,693 | 0 | 0 | 0 | For |
| Pacific Life | 38,685 | 0 | 0 | 0 | For |
| Voya | 36,956 | 0 | 0 | 0 | For |
| Global X | 36,197 | 0 | 0 | 0 | For |
| Brighthouse | 34,296 | 0 | 0 | 0 | For |
| ProShares | 34,027 | 0 | 0 | 0 | For |
| Nationwide | 31,395 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 21,619 | 0 | 0 | 0 | For |
| SEI | 18,400 | 0 | 0 | 0 | For |
Showing the 25 largest of 39 asset managers. See all 39 in the interactive database.
Combines 3 wordings of this item as funds reported it.
89% Approved · of votes cast
Description as filed by funds: To approve an advisory vote on named executive officer compensation.
OCULAR THERAPEUTIX INC.’s own tally for this item (“(2) The Company's stockholders approved a non-binding, advisory proposal regarding the compensation of the Company's named executive officers.”): 76,321,509 for, 9,265,164 against — passed, per its Form 8-K filed June 14, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “(2) The Company's stockholders approved a non-binding, advisory proposal regarding the compensation of the Company's named executive officers.”
Support: 89% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 7,022,809 | 0 | 0 | 0 | For |
| Fidelity | 2,186,730 | 0 | 0 | 0 | For |
| TIAA | 824,620 | 0 | 0 | 0 | For |
| T. Rowe Price | 774,875 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 0 | 750,100 | 0 | 0 | Against |
| Invesco | 0 | 519,167 | 0 | 0 | Against |
| BlackRock | 505,753 | 0 | 0 | 0 | For |
| Charles Schwab | 316,471 | 0 | 0 | 0 | For |
| Equitable | 311,496 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 176,912 | 0 | 0 | 0 | For |
| State Street | 157,171 | 41 | 0 | 0 | For |
| PARADIGM FUNDS | 140,000 | 0 | 0 | 0 | For |
| Lincoln Financial | 92,900 | 0 | 0 | 0 | For |
| 1290 Funds | 80,111 | 0 | 0 | 0 | For |
| John Hancock | 66,703 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 56,981 | 0 | 0 | 0 | For |
| Goldman Sachs | 48,693 | 0 | 0 | 0 | For |
| Pacific Life | 38,685 | 0 | 0 | 0 | For |
| Voya | 36,956 | 0 | 0 | 0 | For |
| Global X | 0 | 36,197 | 0 | 0 | Against |
| Brighthouse | 34,296 | 0 | 0 | 0 | For |
| ProShares | 34,027 | 0 | 0 | 0 | For |
| Nationwide | 30,436 | 959 | 0 | 0 | For |
| Bridge Builder Trust | 21,619 | 0 | 0 | 0 | For |
| SEI | 0 | 18,400 | 0 | 0 | Against |
Fund voting reports, all 39 managers: 13,053,750 for, 1,336,395 against. Showing the 25 largest; see all in the interactive database.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Deep Track Capital, LP | 9,230,769 | 0 | 0 | 0 | For |
| VR Adviser, LLC | 7,775,760 | 0 | 0 | 0 | For |
| Avoro Capital Advisors LLC | 7,148,936 | 0 | 0 | 0 | For |
| Logos Global Management LP | 0 | 3,768,953 | 0 | 0 | Against |
| Citadel | 3,187,501 | 0 | 0 | 0 | For |
| DELTEC ASSET MANAGEMENT LLC | 2,295,333 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 2,273,374 | 0 | 0 | 0 | For |
| FRANKLIN ADVISERS INC | 0 | 2,168,284 | 0 | 0 | Against |
| BlackRock | 2,089,212 | 9,118 | 0 | 0 | For |
| Octagon Capital Advisors LP | 1,839,632 | 0 | 0 | 0 | For |
| GREAT POINT PARTNERS LLC | 1,728,723 | 0 | 0 | 0 | For |
| State Street | 1,692,676 | 4,340 | 0 | 0 | For |
| PERCEPTIVE ADVISORS LLC | 1,394,406 | 0 | 0 | 0 | For |
| ACUTA CAPITAL PARTNERS, LLC | 1,322,878 | 0 | 0 | 0 | For |
| T. Rowe Price | 968,094 | 0 | 0 | 0 | For |
| Nuveen | 832,780 | 0 | 0 | 0 | For |
| Artia Global Partners LP | 775,885 | 0 | 0 | 0 | For |
| Point72 | 704,767 | 0 | 0 | 0 | For |
| Opaleye Management Inc. | 698,138 | 0 | 0 | 0 | For |
| Northern Trust | 654,702 | 530 | 0 | 0 | For |
| Invesco | 0 | 545,524 | 0 | 0 | Against |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 375,000 | 0 | 0 | 0 | For |
| Charles Schwab | 316,471 | 0 | 0 | 0 | For |
| Wellington | 0 | 242,912 | 0 | 0 | Against |
| Vanguard | 237,014 | 0 | 0 | 0 | For |
Institutional-manager reports, all 113 managers: 49,099,115 for, 7,448,644 against. Showing the 25 largest; see all in the interactive database.
Combines 4 wordings of this item as funds reported it.
99.2% Approved · of votes cast
Description as filed by funds: To ratify the appointment of PricewaterhouseCoopers LLP as Ocular Therapeutix's independent registered public accounting firm for the fiscal year ending December 31, 2024.
OCULAR THERAPEUTIX INC.’s own tally for this item (“(5) The Company's stockholders ratified the selection of PricewaterhouseCoopers LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2024.”): 119,634,478 for, 859,430 against — passed, per its Form 8-K filed June 14, 2024 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “(5) The Company's stockholders ratified the selection of PricewaterhouseCoopers LLP as its independent registered public accounting firm for the fiscal year ending December 31, 2024.”
Support: 99.2% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 39 asset managers below reported 14,390,123 for, 22 against.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 7,022,809 | 0 | 0 | 0 | For |
| Fidelity | 2,186,730 | 0 | 0 | 0 | For |
| TIAA | 824,620 | 0 | 0 | 0 | For |
| T. Rowe Price | 774,875 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 750,100 | 0 | 0 | 0 | For |
| Invesco | 519,167 | 0 | 0 | 0 | For |
| BlackRock | 505,753 | 0 | 0 | 0 | For |
| Charles Schwab | 316,471 | 0 | 0 | 0 | For |
| Equitable | 311,496 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 176,912 | 0 | 0 | 0 | For |
| State Street | 157,190 | 22 | 0 | 0 | For |
| PARADIGM FUNDS | 140,000 | 0 | 0 | 0 | For |
| Lincoln Financial | 92,900 | 0 | 0 | 0 | For |
| 1290 Funds | 80,111 | 0 | 0 | 0 | For |
| John Hancock | 66,703 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 56,981 | 0 | 0 | 0 | For |
| Goldman Sachs | 48,693 | 0 | 0 | 0 | For |
| Pacific Life | 38,685 | 0 | 0 | 0 | For |
| Voya | 36,956 | 0 | 0 | 0 | For |
| Global X | 36,197 | 0 | 0 | 0 | For |
| Brighthouse | 34,296 | 0 | 0 | 0 | For |
| ProShares | 34,027 | 0 | 0 | 0 | For |
| Nationwide | 31,395 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 21,619 | 0 | 0 | 0 | For |
| SEI | 18,400 | 0 | 0 | 0 | For |
Showing the 25 largest of 39 asset managers. See all 39 in the interactive database.
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 154,704,086 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 4.54% |
| 2 | Fidelity | 1.41% |
| 3 | TIAA | 0.53% |
| 4 | T. Rowe Price | 0.50% |
| 5 | FRANKLIN STRATEGIC SERIES | 0.48% |
| 6 | Invesco | 0.34% |
| 7 | BlackRock | 0.33% |
| 8 | Charles Schwab | 0.20% |
| 9 | Equitable | 0.20% |
| 10 | QUANTITATIVE MASTER SERIES LLC | 0.11% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Deep Track Capital, LP | 5.97% |
| 2 | VR Adviser, LLC | 5.03% |
| 3 | Avoro Capital Advisors LLC | 4.62% |
| 4 | Logos Global Management LP | 2.44% |
| 5 | Citadel | 2.06% |
| 6 | DELTEC ASSET MANAGEMENT LLC | 1.48% |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 1.47% |
| 8 | FRANKLIN ADVISERS INC | 1.40% |
| 9 | BlackRock | 1.36% |
| 10 | Octagon Capital Advisors LP | 1.19% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.
| Holder | % outstanding | Disclosure |
|---|---|---|
| FMR (Fidelity) | 20.55% | 13F |
| BlackRock | 6.82% | 13F |
| Vanguard Group | 5.92% | 13F |
| Citadel Advisors | 3.64% | 13F |
| Geode Capital | 1.61% | 13F |
| Morgan Stanley | 1.59% | 13F |
| State Street | 1.55% | 13F |
| Franklin Templeton | 1.40% | 13F |
| Nuveen | 0.78% | 13F |
| Northern Trust | 0.63% | 13F |
Percentages above are of 154,704,086 shares outstanding, as reported by OCULAR THERAPEUTIX INC. on its Form 10-Q dated March 31, 2024 (see the filing on EDGAR). This is the count contemporaneous with the 2023-2024 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from OCULAR THERAPEUTIX INC.’s 10-Q dated March 31, 2024. This page is a static snapshot rebuilt weekly on October 18, 2026; a live search always shows the current data.
At OCULAR THERAPEUTIX INC.'s shareholder meeting held June 12, 2024, in the 2023-2024 proxy season, 138 asset managers reported how they voted on 6 ballot items in their SEC Form N-PX filings, covering 844 separate fund positions. On the most widely held item on that ballot — To approve an advisory vote on named executive officer compensation. — OCULAR THERAPEUTIX INC.'s filing reports the proposal as approved, with 89% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: OCULAR THERAPEUTIX INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 14, 2024.
OCULAR THERAPEUTIX INC. proxy season coverage: 2023-2024 (this page) · 2024-2025 · 2025-2026.
Download data (CSV): ballot items · votes by manager · column guide.